Report Overview

The South Korea sodium glucose co-transporter 2 (SGLT 2) inhibitor market size stood at around USD 90.18 million in 2019 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.

SGLT2 inhibitors are a class of medications used to treat type 2 diabetes. They are also called sodium-glucose transport protein 2 inhibitors or gliflozins. SGLT2 inhibitors prevent the reabsorption of glucose from blood that is filtered through kidneys, therefore facilitating glucose excretion in the urine. This helps reduce blood sugar levels. In 2019, the domestic SGLT-2 inhibitor market has grown by about 40%. SGLT-2 inhibitors are expanding their indications in the area of heart failure treatment, and growth is expected to continue due to the high possibility of expanding benefits with DPP-4 inhibitors in the domestic diabetes treatment area.



Market Drivers

The size of the SGLT-2 inhibitor market is growing because of its multi-faceted benefits. It is used not only for heart and kidney effects, but also for weight loss, leading domestic and international guidelines recommend SGLT-2 inhibitors over other oral diabetes treatments, and heart failure confirmed through cardiovascular studies.

The SGLT2 market has a high potential for growth, dueto the increasing number of diabetic patients and their need for drugs that helpreduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.